David E. Stec, Ph.D.

Former Postdoctoral Fellow (1996-2000)

 

Current Position:

Assistant Professor of Physiology

University of Mississippi Medical Center

Jackson, MS

http://physiology.umc.edu/

 

Publications from the Sigmund Lab:

1:	Stec DE, Keen HL, Sigmund CD.
	Lower blood pressure in floxed angiotensinogen mice after adenoviral delivery of Cre-recombinase. Hypertension. 2002 Feb;39(2 Pt 2):629-33.

2:	Stec DE, Morimoto S, Sigmund CD.
	Vectors for high-level expression of cDNAs controlled by tissue-specific promoters in transgenic mice. Biotechniques. 2001 Aug;31(2):256-8, 260. No abstract available.

3:	Stec DE, Sigmund CD.
	Physiological insights from genetic manipulation of the renin-angiotensin system. News Physiol Sci. 2001 Apr;16:80-4. Review.

4:	Ding Y, Stec DE, Sigmund CD.
	Genetic evidence that lethality in angiotensinogen-deficient mice is due to loss of systemic but not renal angiotensinogen. J Biol Chem. 2001 Mar 9;276(10):7431-6. Epub 2000 Nov 28.

5:	Stec DE, Davisson RL, Haskell RE, Davidson BL, Sigmund CD.
	Efficient liver-specific deletion of a floxed human angiotensinogen transgene by adenoviral delivery of Cre recombinase in vivo. J Biol Chem. 1999 Jul 23;274(30):21285-90.

6:	Davisson RL, Ding Y, Stec DE, Catterall JF, Sigmund CD.
	Novel mechanism of hypertension revealed by cell-specific targeting of human angiotensinogen in transgenic mice. Physiol Genomics. 1999 Jul 15;1(1):3-9.

7:	Stec DE, Sigmund CD.
	Modifiable gene expression in mice: kidney-specific deletion of a target gene via the cre-loxP system. Exp Nephrol. 1998 Nov-Dec;6(6):568-75. Review.

8:	Stec DE, Davisson RL, Sigmund CD.
	Transgenesis and gene targeting in the mouse; tools for studying genetic determinants of hypertension. Trends Cardiovasc Med. 1998 Aug;8(6):256-64.